Clever, Personable, and Unconventional: Pharvaris’ Exciting Business Update and Expanded Development Program for Deucrictibant

ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS) Announces Major Developments in HAE Treatment Introduction Pharvaris, a leading biopharmaceutical company, has recently unveiled plans for the groundbreaking CHAPTER-3 Phase 3 study of deucrictibant extended-release tablets. This study aims to revolutionize the prophylactic treatment of hereditary angioedema (HAE) attacks, while also introducing new…

Read More

Discover the Heart of Nova Minerals: Bulk Antimony Material Collected for Test Work at the Estelle Gold-Antimony Project in Alaska

The Promise of Antimony-Gold Prospects in Alaska Exploring Nova Minerals Limited’s Exciting Updates On September 5th, 2024, Nova Minerals Limited announced exciting updates on its Antimony-Gold prospects at Stibium and Styx on its flagship Estelle Project in Alaska. This project, spanning over 500km2 in the prolific Tintina Gold Belt, holds immense potential for both Antimony…

Read More

Join the Fun: Don’t Miss the Deadline of September 6, 2024 to Contact The Gross Law Firm and Join the Class Action Suit Against ICU!

Welcome Fellow Shareholders! Gross Law Firm Notice regarding SeaStar Medical Holding Corporation Hey there everyone, gather around for some exciting news! The Gross Law Firm has just issued a notice to shareholders of SeaStar Medical Holding Corporation (NASDAQ: ICU). Don’t panic, this is just a reminder to stay informed and up to date with the…

Read More

Uncovering Gold: Val-d’Or Resource Surges to Over 6.7 Million Ounces – A 77% Increase!

Welcome to the Gold Rush: Val-d’Or East Properties Update Exciting News for Investors If you’re into gold mining, then you’re in for a treat! The latest update on the Val-d’Or East properties has investors buzzing with excitement. Total resources for all properties now stand at an impressive 6,728,600 ounces Measured and Indicated (M&I) and 3,277,100…

Read More

Revolutionizing Heart Health: Venus Medtech’s Venus ViTae Successfully Completes First Two Implantations in Groundbreaking Smart Align Clinical Study

Venus Medtech Makes Breakthrough in TAVR Technology Revolutionizing TAVR with Venus-Vitae System In an exciting development for the medical world, Venus Medtech has successfully completed two inaugural implantations of its next-generation balloon-expandable dry-tissue transcatheter aortic valve replacement (TAVR) system, Venus-Vitae. This achievement marks a significant milestone in the field of transcatheter structural heart valvular therapies,…

Read More